Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site

Advertisement - Covance

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing, solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion, which will add over 11,000 square feet of production space at the facility, will be segregated and designed to handle cytotoxic and highly active products for prescription softgel manufacturing.

The new facilities, which are due to be completed in December 2021, will include two new manufacturing vessels of 40 and 300 liters, which include an automatic cleaning system and an innovative mixing device suitable for very high viscosity formulations, a capsule filling line and six drying tunnels. This will add a capacity of over 10 million doses per annum to the site, which supplies products to the Latin American, U.S. and European markets.

“This investment will allow the site to grow and handle a wider range of projects, reacting to the increased demands of the industry for high potency treatments in areas such as oncology,” commented Sergio Alter, Vice President & General Manager Softgel Technologies, Latin America. He added, “Not only will this increase the capacity of the site, but the design of the new facility will see it meet the highest standards of environmental and energy efficiency.”

Catalent’s 265,000 square-foot-facility in Buenos Aires currently houses softgel manufacturing operations, providing customers with a full range of development services, from formulation to packaging.

ABOUT CATALENT

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including approximately 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey.